Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Elisabetta Todisco, F. Ciceri, Cristina Boschini, Ada F. Giglio, A. Bacigalupo, F. Patriarca, I. Donnini, E. P. Alessandrino, Giorgio W. Arcese, A. P. Iori, P. Marenco, Irene Cavattoni, Patrizia Chiusolo, Elisabetta Terruzzi, L. Castagna, A. Santoro, A. Bosi, Elena Oldani, B. Bruno, F. BonifaziAlessandro Rambaldi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The clinical outcome of primary refractory (PRF) AML patients is poor and only a minor proportion of patients is rescued by allogenic hematopoietic stem cell transplantation (HSCT). The identification of pre-HSCT variables may help to determine PRF AML patients who can most likely benefit from HSCT. We analyzed PRF AML patients transplanted between 1999 and 2012 from a sibling, unrelated donor or a cord blood unit. Overall, 227 patients from 26 Gruppo Italiano Trapianto di Midollo Osseo e Terapia cellulare centers were included in the analysis. At 3 years, the overall survival was 14%. By multivariate analysis, the number of chemotherapy cycles, (hazard ratio (HR): 1.87; 95% confidence interval (CI): 1.24–2.85; P=0.0028), the percentage of bone marrow or peripheral blood blasts (HR: 1.75; 95% CI: 1.16–2.64; P=0.0078), the adverse cytogenetic (HR: 1.44; 95% CI: 1.00–2.07; P=0.0508) and the age of patients (HR: 1.77; 95% CI: 1.08–2.88; P=0.0223) remained significantly associated with survival. Thus, we set up a new score predicting at 3 years after transplantation, an overall survival probability of 32% for patients with score 0 (no or 1 prognostic factor), 10% for patients with score 1 (2 prognostic factors) and 3% for patients with score 2 (3 or 4 prognostic factors).Bone Marrow Transplantation advance online publication, 9 January 2017; doi:10.1038/bmt.2016.325.

Original languageEnglish
JournalBone Marrow Transplantation
DOIs
Publication statusAccepted/In press - Jan 9 2017

Fingerprint

Acute Myeloid Leukemia
Transplants
Hematopoietic Stem Cell Transplantation
Confidence Intervals
Survival
Unrelated Donors
Bone Marrow Transplantation
Fetal Blood
Cytogenetics
Publications
Siblings
Multivariate Analysis
Transplantation
Bone Marrow
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia : a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). / Todisco, Elisabetta; Ciceri, F.; Boschini, Cristina; Giglio, Ada F.; Bacigalupo, A.; Patriarca, F.; Donnini, I.; Alessandrino, E. P.; Arcese, Giorgio W.; Iori, A. P.; Marenco, P.; Cavattoni, Irene; Chiusolo, Patrizia; Terruzzi, Elisabetta; Castagna, L.; Santoro, A.; Bosi, A.; Oldani, Elena; Bruno, B.; Bonifazi, F.; Rambaldi, Alessandro.

In: Bone Marrow Transplantation, 09.01.2017.

Research output: Contribution to journalArticle

Todisco, E, Ciceri, F, Boschini, C, Giglio, AF, Bacigalupo, A, Patriarca, F, Donnini, I, Alessandrino, EP, Arcese, GW, Iori, AP, Marenco, P, Cavattoni, I, Chiusolo, P, Terruzzi, E, Castagna, L, Santoro, A, Bosi, A, Oldani, E, Bruno, B, Bonifazi, F & Rambaldi, A 2017, 'Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)', Bone Marrow Transplantation. https://doi.org/10.1038/bmt.2016.325
Todisco, Elisabetta ; Ciceri, F. ; Boschini, Cristina ; Giglio, Ada F. ; Bacigalupo, A. ; Patriarca, F. ; Donnini, I. ; Alessandrino, E. P. ; Arcese, Giorgio W. ; Iori, A. P. ; Marenco, P. ; Cavattoni, Irene ; Chiusolo, Patrizia ; Terruzzi, Elisabetta ; Castagna, L. ; Santoro, A. ; Bosi, A. ; Oldani, Elena ; Bruno, B. ; Bonifazi, F. ; Rambaldi, Alessandro. / Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia : a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). In: Bone Marrow Transplantation. 2017.
@article{51a94e08f75b49f99600a419350264f3,
title = "Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)",
abstract = "The clinical outcome of primary refractory (PRF) AML patients is poor and only a minor proportion of patients is rescued by allogenic hematopoietic stem cell transplantation (HSCT). The identification of pre-HSCT variables may help to determine PRF AML patients who can most likely benefit from HSCT. We analyzed PRF AML patients transplanted between 1999 and 2012 from a sibling, unrelated donor or a cord blood unit. Overall, 227 patients from 26 Gruppo Italiano Trapianto di Midollo Osseo e Terapia cellulare centers were included in the analysis. At 3 years, the overall survival was 14{\%}. By multivariate analysis, the number of chemotherapy cycles, (hazard ratio (HR): 1.87; 95{\%} confidence interval (CI): 1.24–2.85; P=0.0028), the percentage of bone marrow or peripheral blood blasts (HR: 1.75; 95{\%} CI: 1.16–2.64; P=0.0078), the adverse cytogenetic (HR: 1.44; 95{\%} CI: 1.00–2.07; P=0.0508) and the age of patients (HR: 1.77; 95{\%} CI: 1.08–2.88; P=0.0223) remained significantly associated with survival. Thus, we set up a new score predicting at 3 years after transplantation, an overall survival probability of 32{\%} for patients with score 0 (no or 1 prognostic factor), 10{\%} for patients with score 1 (2 prognostic factors) and 3{\%} for patients with score 2 (3 or 4 prognostic factors).Bone Marrow Transplantation advance online publication, 9 January 2017; doi:10.1038/bmt.2016.325.",
author = "Elisabetta Todisco and F. Ciceri and Cristina Boschini and Giglio, {Ada F.} and A. Bacigalupo and F. Patriarca and I. Donnini and Alessandrino, {E. P.} and Arcese, {Giorgio W.} and Iori, {A. P.} and P. Marenco and Irene Cavattoni and Patrizia Chiusolo and Elisabetta Terruzzi and L. Castagna and A. Santoro and A. Bosi and Elena Oldani and B. Bruno and F. Bonifazi and Alessandro Rambaldi",
year = "2017",
month = "1",
day = "9",
doi = "10.1038/bmt.2016.325",
language = "English",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia

T2 - a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

AU - Todisco, Elisabetta

AU - Ciceri, F.

AU - Boschini, Cristina

AU - Giglio, Ada F.

AU - Bacigalupo, A.

AU - Patriarca, F.

AU - Donnini, I.

AU - Alessandrino, E. P.

AU - Arcese, Giorgio W.

AU - Iori, A. P.

AU - Marenco, P.

AU - Cavattoni, Irene

AU - Chiusolo, Patrizia

AU - Terruzzi, Elisabetta

AU - Castagna, L.

AU - Santoro, A.

AU - Bosi, A.

AU - Oldani, Elena

AU - Bruno, B.

AU - Bonifazi, F.

AU - Rambaldi, Alessandro

PY - 2017/1/9

Y1 - 2017/1/9

N2 - The clinical outcome of primary refractory (PRF) AML patients is poor and only a minor proportion of patients is rescued by allogenic hematopoietic stem cell transplantation (HSCT). The identification of pre-HSCT variables may help to determine PRF AML patients who can most likely benefit from HSCT. We analyzed PRF AML patients transplanted between 1999 and 2012 from a sibling, unrelated donor or a cord blood unit. Overall, 227 patients from 26 Gruppo Italiano Trapianto di Midollo Osseo e Terapia cellulare centers were included in the analysis. At 3 years, the overall survival was 14%. By multivariate analysis, the number of chemotherapy cycles, (hazard ratio (HR): 1.87; 95% confidence interval (CI): 1.24–2.85; P=0.0028), the percentage of bone marrow or peripheral blood blasts (HR: 1.75; 95% CI: 1.16–2.64; P=0.0078), the adverse cytogenetic (HR: 1.44; 95% CI: 1.00–2.07; P=0.0508) and the age of patients (HR: 1.77; 95% CI: 1.08–2.88; P=0.0223) remained significantly associated with survival. Thus, we set up a new score predicting at 3 years after transplantation, an overall survival probability of 32% for patients with score 0 (no or 1 prognostic factor), 10% for patients with score 1 (2 prognostic factors) and 3% for patients with score 2 (3 or 4 prognostic factors).Bone Marrow Transplantation advance online publication, 9 January 2017; doi:10.1038/bmt.2016.325.

AB - The clinical outcome of primary refractory (PRF) AML patients is poor and only a minor proportion of patients is rescued by allogenic hematopoietic stem cell transplantation (HSCT). The identification of pre-HSCT variables may help to determine PRF AML patients who can most likely benefit from HSCT. We analyzed PRF AML patients transplanted between 1999 and 2012 from a sibling, unrelated donor or a cord blood unit. Overall, 227 patients from 26 Gruppo Italiano Trapianto di Midollo Osseo e Terapia cellulare centers were included in the analysis. At 3 years, the overall survival was 14%. By multivariate analysis, the number of chemotherapy cycles, (hazard ratio (HR): 1.87; 95% confidence interval (CI): 1.24–2.85; P=0.0028), the percentage of bone marrow or peripheral blood blasts (HR: 1.75; 95% CI: 1.16–2.64; P=0.0078), the adverse cytogenetic (HR: 1.44; 95% CI: 1.00–2.07; P=0.0508) and the age of patients (HR: 1.77; 95% CI: 1.08–2.88; P=0.0223) remained significantly associated with survival. Thus, we set up a new score predicting at 3 years after transplantation, an overall survival probability of 32% for patients with score 0 (no or 1 prognostic factor), 10% for patients with score 1 (2 prognostic factors) and 3% for patients with score 2 (3 or 4 prognostic factors).Bone Marrow Transplantation advance online publication, 9 January 2017; doi:10.1038/bmt.2016.325.

UR - http://www.scopus.com/inward/record.url?scp=85008685933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008685933&partnerID=8YFLogxK

U2 - 10.1038/bmt.2016.325

DO - 10.1038/bmt.2016.325

M3 - Article

AN - SCOPUS:85008685933

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -